• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Jon L. Hart named CEO of med fusion

Jon L. Hart named CEO of med fusion

April 11, 2014
CenterWatch Staff

med fusion, an integrated, advanced laboratory and clinical trials service organization, has appointed Jon L. Hart CEO, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing lab and clinical trial support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model.

Hart will lead the company’s efforts to introduce more targeted diagnostics, reduce episode of care costs and enhance system efficiencies. He also will spearhead the company’s recent collaboration with U.S. Oncology Network. In 2013, physicians in the Network selected med fusion as one of their preferred diagnostic laboratories. The relationship’s aim is to advance the delivery of high-quality, precision medicine—the tailoring of medical treatment to the genetic characteristics found in each patient’s tumor—and the appropriate use of molecular diagnostics. Additionally, Hart will lead med fusion and the Network’s recent pilot program on genomic testing for non small cell lung cancer (NSCLC) patients. For the pilot, physicians in the Network will test their ability to adopt a standard molecular testing approach for all NSCLC patients. The standard is a targeted biomarker panel developed by med fusion and physicians in the Network, and the pilot’s success will demonstrate the Network’s ability to lead community oncology in precision medicine.

“There are a lot of exciting initiatives happening right now at med fusion and within the healthcare industry as a whole that could benefit the delivery of high-quality patient care,” said Hart. “Precision medicine is one of them. I am pleased to announce that the company recently raised a second round of funding of 71 million dollars designed to expand our capabilities in this area. I am honored to join med fusion’s top notch team and move its precision medicine initiatives forward.”

Previously, Hart was president and CEO of Aurora Diagnostics, a national anatomic pathology provider based in Palm Beach Gardens, Fla. Prior, Hart led a business turnaround when he was in charge of Genzyme Genetics, the esoteric laboratory division of Genzyme in Cambridge, Mass. Hart has held several leadership roles throughout his career for organizations such as Arthur Young & Company in Atlanta, Ga. and Quest Diagnostics in Madison, N.J.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing